EyePoint, Inc. (EYPT)

Market Cap	1.11B +161.0%
Revenue (ttm)	31.37M -27.5%
Net Income	-231.96M
EPS	-3.17
Shares Out	83.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	681,070
Open	13.37
Previous Close	13.20
Day's Range	13.05 - 13.53
52-Week Range	3.91 - 19.11
Beta	1.79
Analysts	Strong Buy
Price Target	31.80 (+139.1%)
Earnings Date	Mar 4, 2026

About EYPT

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 27, 2005
• Employees: 214
• Stock Exchange: NASDAQ
• Ticker Symbol: EYPT
• Website: https://eyepoint.bio

Financial Performance

In 2025, EyePoint's revenue was $31.37 million, a decrease of -27.50% compared to the previous year's $43.27 million. Losses were -$231.96 million, 77.2% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for EYPT stock is "Strong Buy." The 12-month stock price target is $31.8, which is an increase of 139.10% from the latest price.

Price Target

$31.8

(139.10% upside)

Analyst Consensus: Strong Buy